Saturday 17 October 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.
175.20
8.97
−4.87%
Follow RGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 1.99% | 2.51% | 2.40% | 0.08% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 7 | 6 | 6 | |
| 1.42% | 1.78% | 1.69% | 0.06% | ||
ROIC |
2.18% | 2.16% | 1.83% | 0.03% | |
Return on Tangible Assets |
3.36% | 4.25% | 4.12% | 0.15% | |
Average Days of Receivables |
73.32 | 72.47 | 78.41 | 76.81 | |
Free Cash Flow per Share |
1.96 | 1.86 | 1.63 | 1.87 | |
Free Cash Flow |
110.35 | 104.66 | 91.93 | 105.23 | |
Capital Expenditures |
(24.51) | (26.05) | (25.49) | (25.66) | |
| Other line items | |||||
Cash ROIC |
3.18% | 3.05% | 2.69% | 3.12% | |
Accounts Receivable Turnover |
4.99 | 5.11 | 5.04 | 5.09 | |
Accounts Payable Turnover |
12.40 | 11.70 | 11.33 | 15.13 | |
Inventory Turnover |
2.13 | 2.17 | 2.25 | 2.24 | |
Average Days of Payables |
33.24 | 35.12 | 31.12 | 27.96 | |
Days of Inventory on Hand |
186.65 | 181.65 | 176.75 | 152.32 | |
Tax Rate |
(0.20) | (0.09) | (0.22) | (0.63) | |
Research and Development Expense of Revenue |
7.26% | 7.40% | 7.34% | 7.34% | |
Selling, General and Administrative Expense of Revenue |
38.47% | 38.82% | 39.35% | 38.95% | |
Share Based Compensation of Revenue |
4.24% | 4.41% | 4.42% | 4.38% | |
Interest Coverage |
2.92 | 2.95 | 2.56 | 0.04 | |
Operating CF/Net income |
3.25 | 2.54 | 2.40 | 75.31 | |
Depreciation/Fixed assets |
0.58 | 0.56 | 0.51 | 0.49 | |
Capex/Depreciation |
(0.25) | (0.27) | (0.27) | (0.27) | |
Revenue per Share |
13.92 | 13.55 | 13.13 | 12.58 | |
Operating CF per Share |
2.39 | 2.32 | 2.09 | 2.33 | |
Capex per Share |
(0.43) | (0.46) | (0.45) | (0.46) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates